Autologous Marrow Mesenchymal Stem Cell Driving Bone Regeneration in a Rabbit Model of Femoral Head Osteonecrosis

• Egile Nagusiak: Ilenia Mastrolia (Egilea), Andrea Giorgini (Egilea), Alba Murgia (Egilea), Pietro Loschi (Egilea), Tiziana Petrachi (Egilea), Valeria Rasini (Egilea), Massimo Pinelli (Egilea), Valentina Pinto (Egilea), Francesca Lolli (Egilea), Chiara Chiavelli (Egilea), Giulia Grisendi (Egilea), Maria Cristina Baschieri (Egilea), Giorgio De Santis (Egilea), Fabio Catani (Egilea), Massimo Dominici (Egilea), Elena Veronesi (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Gaia

Osteonecrosis of the femoral head (ONFH) is a progressive degenerative disease that ultimately requires a total hip replacement. Mesenchymal stromal/stem cells (MSCs), particularly the ones isolated from bone marrow (BM), could be promising tools to restore bone tissue in ONFH. Here, we established a rabbit model to mimic the pathogenic features of human ONFH and to challenge an autologous MSC-based treatment. ON has been originally induced by the synergic combination of surgery and steroid administration. Autologous BM-MSCs were then implanted in the FH, aiming to restore the damaged tissue. Histological analyses confirmed bone formation in the BM-MSC treated rabbit femurs but not in the controls. In addition, the model also allowed investigations on BM-MSCs isolated before (ON-BM-MSCs) and after (ON+BM-MSCs) ON induction to dissect the impact of ON damage on MSC behavior in an affected microenvironment, accounting for those clinical approaches foreseeing MSCs generally isolated from affected patients. BM-MSCs, isolated before and after ON induction, revealed similar growth rates, immunophenotypic profiles, and differentiation abilities regardless of the ON. Our data support the use of ON+BM-MSCs as a promising autologous therapeutic tool to treat ON, paving the way for a more consolidated use into the clinical settings.

Alearen deskribapena

10.3390/pharmaceutics14102127
1999-4923